Phase III Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and Open-label, Non-comparative Long-term Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases) -

Trial Profile

Phase III Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and Open-label, Non-comparative Long-term Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases) -

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Linaclotide (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 29 Jan 2017 Primary endpoint (Change from baseline in weekly mean SBM frequency during one week of administration (Part I)) has been met, according to Astellas Pharma media release.
    • 19 Dec 2016 Top-line data from this trial are expected in 2017, according to an Ironwood Pharmaceuticals Inc. media release.
    • 01 Nov 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top